Cell Therapy Facility Design: Significant capital has been invested globally to design and construct autologous cell therapy facilities. Many cell therapy manufacturers are now investigating next gen allogeneic replacements for their existing therapies, resulting in the need for flexible facilities that can accommodate both processes. In this presentation, experts in cell therapy facility design from PM Group, Tyler Underhill and Daryl Kern, AIA will present transitioning existing facilities and operations from autologous to allogeneic, and how buildings can adapt. Tyler and Daryl will discuss the different attributes of autologous and allogeneic cell therapy facilities, the manufacturing challenges in transitioning between the two, and how to incorporate adaptability and/or flexibility without affecting the therapy quality. This presentation is best suited for pharmaceutical professionals who would like to broaden their understanding of cell therapy facility design.

In-person attendance is encouraged, but there will also be a virtual option to attend this program.

Agenda:

5:00 - 6:00 PM - Networking (Cash Bar)
6:00 - 6:30 PM - Buffet Dinner
6:30 - 8:00 PM - Presentations

Speakers:

Tyler Underhill

Tyler Underhill is a Senior Director of Biologics and Cell/Gene Therapies at PM Group's Boston Office. He is an accomplished Process Engineer with more than 10 years of experience in the pharmaceutical and biopharmaceutical industries. 

Daryl Kern

Daryl Kern is Director of Architecture and Principal Architect at PM Group's Philadelphia Office. Daryl is a Process Architect specializing in the design of manufacturing facilities and laboratories that support regenerative medicines.

www.pmgroup-global.com 

Registration will open at 5:00pm and a buffet dinner will be served at 5:30pm, followed by the presentations. One complimentary drink ticket will be provided, followed by a cash bar.

The program will conclude at 8:00pm.

Location:

Thank you to our sponsors for this event: